Spanish Red Biotech Pipeline

MSD

MK1084 + Pembrolizumab

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: A Phase 1 Study with MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Phase: 1Phase I in Spain